Shuang Dai
Shuang Dai
1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
2School of Pharmaceutical Sciences, Central South University, Changsha, China
3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
1,2,3,†,
Yuanliang Yan
Yuanliang Yan
1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
1,3,†,
Zhijie Xu
Zhijie Xu
1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
4Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
1,3,4,
Shuangshuang Zeng
Shuangshuang Zeng
1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
1,3,
Long Qian
Long Qian
1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
1,3,
Lei Huo
Lei Huo
5Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
5,
Xuejun Li
Xuejun Li
5Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
5,
Lunquan Sun
Lunquan Sun
6Center for Molecular Medicine, Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
6,
Zhicheng Gong
Zhicheng Gong
1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
1,3,*
1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
2School of Pharmaceutical Sciences, Central South University, Changsha, China
3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
4Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
5Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
6Center for Molecular Medicine, Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Edited by: Julie Gavard, Institut National de la Santé et de la Recherche Médicale (INSERM), France
Reviewed by: Julie Gavard, Institut National de la Santé et de la Recherche Médicale (INSERM), France
✉*Correspondence: Zhicheng Gong, gongzhicheng@csu.edu.cn
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
†These authors have contributed equally to this work
Received 2019 Sep 30; Accepted 2019 Oct 28; Collection date 2019.
Keywords: glioblastomas, temozolomide, resistance, SCD1, Akt signaling
Copyright © 2019 Dai, Yan, Xu, Zeng, Qian, Huo, Li, Sun and Gong
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
